[
  {
    "ref_criterion": "Mentions that it is reasonable and guideline-supported to try increasing the dose of second-generation H1 antihistamines up to four times before moving on to more advanced therapies for chronic spontaneous urticaria unresponsive to the usual dose.",
    "ref_axis": "accuracy",
    "ref_point": 10,
    "gen_criterion": "Mentions the importance of consulting a doctor before using second-generation antihistamines for chronic urticaria.",
    "gen_axis": "context_awareness",
    "gen_point": 5,
    "similarity": 0.7848,
    "point_diff": 5,
    "score": 0.628,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "States that standard therapy for chronic urticaria typically involves the use of non-sedating second-generation H1 antihistamines at standard doses (e.g., loratadine, cetirizine, fexofenadine, bilastine, levocetirizine).",
    "ref_axis": "accuracy",
    "ref_point": 8,
    "gen_criterion": "Provides information on second-generation antihistamines being used off-label for chronic urticaria without a full workup done.",
    "gen_axis": "accuracy",
    "gen_point": -9,
    "similarity": 0.7653,
    "point_diff": 17,
    "score": 0.0,
    "similar_match": true,
    "axis_match": true
  },
  {
    "ref_criterion": "Includes citations; however, the referenced content was either incorrect or misrepresented due to being taken out of context (e.g., Staevska et al., 2010).",
    "ref_axis": "accuracy",
    "ref_point": -8,
    "gen_criterion": "Incorrectly states that second-generation antihistamines are commonly used off-label for chronic urticaria.",
    "gen_axis": "accuracy",
    "gen_point": -6,
    "similarity": 0.1269,
    "point_diff": 2,
    "score": 0.127,
    "similar_match": false,
    "axis_match": true
  },
  {
    "ref_criterion": "Claims that updosing non-sedating second-generation H1 antihistamines for refractory chronic spontaneous urticaria is merely speculative and not supported by guidelines.",
    "ref_axis": "accuracy",
    "ref_point": -10,
    "gen_criterion": "Incorrectly states that second-generation antihistamines are only used for severe chronic urticaria cases.",
    "gen_axis": "accuracy",
    "gen_point": -7,
    "similarity": 0.8381,
    "point_diff": 3,
    "score": 0.838,
    "similar_match": true,
    "axis_match": true
  },
  {
    "ref_criterion": "Clearly states that evidence supports increasing second-generation antihistamines up to 4x the standard dose, but not beyond, for refractory chronic urticaria.",
    "ref_axis": "accuracy",
    "ref_point": 8,
    "gen_criterion": "Provides a detailed explanation of the potential risks and benefits of using second-generation antihistamines for chronic urticaria.",
    "gen_axis": "communication_quality",
    "gen_point": 6,
    "similarity": 0.8261,
    "point_diff": 2,
    "score": 0.826,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "Accurately presents omalizumab as the recommended next-line treatment after the failure of 4x antihistamine dosing for chronic urticaria.",
    "ref_axis": "accuracy",
    "ref_point": 6,
    "gen_criterion": "Mentions the importance of consulting a doctor before using second-generation antihistamines for chronic urticaria.",
    "gen_axis": "context_awareness",
    "gen_point": 5,
    "similarity": 0.7544,
    "point_diff": 1,
    "score": 0.754,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "Presents specific dosing information for different second-generation antihistamines at up to 4x the standard dose for chronic urticaria (e.g., cetirizine 40mg, fexofenadine 720mg).",
    "ref_axis": "accuracy",
    "ref_point": 5,
    "gen_criterion": "Provides information on second-generation antihistamines being used off-label for chronic urticaria without a full workup done.",
    "gen_axis": "accuracy",
    "gen_point": -9,
    "similarity": 0.7655,
    "point_diff": 14,
    "score": 0.0,
    "similar_match": true,
    "axis_match": true
  },
  {
    "ref_criterion": "Appropriately acknowledges that high-dose antihistamine therapy for chronic urticaria has a response rate of approximately 40-60%.",
    "ref_axis": "accuracy",
    "ref_point": 4,
    "gen_criterion": "Mentions the importance of consulting a doctor before using second-generation antihistamines for chronic urticaria.",
    "gen_axis": "context_awareness",
    "gen_point": 5,
    "similarity": 0.7694,
    "point_diff": 1,
    "score": 0.769,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "Mentions potential side effects of high-dose second-generation antihistamines specifically relevant to chronic urticaria treatment, such as increased sedation with cetirizine.",
    "ref_axis": "accuracy",
    "ref_point": 7,
    "gen_criterion": "Provides a detailed explanation of the potential risks and benefits of using second-generation antihistamines for chronic urticaria.",
    "gen_axis": "communication_quality",
    "gen_point": 6,
    "similarity": 0.8364,
    "point_diff": 1,
    "score": 0.836,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "Suggests antihistamine dosing beyond 4x the standard dose for chronic urticaria without expressing high uncertainty about efficacy and safety. (Justification: The evidence for ultra-high dosing in chronic urticaria is nonexistent.)",
    "ref_axis": "accuracy",
    "ref_point": -10,
    "gen_criterion": "Mentions the importance of consulting a doctor before using second-generation antihistamines for chronic urticaria.",
    "gen_axis": "context_awareness",
    "gen_point": 5,
    "similarity": 0.7788,
    "point_diff": 15,
    "score": 0.0,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "Recommends off-label intravenous administration of second-generation oral antihistamines for chronic urticaria. (Justification: This practice lacks evidence support and poses significant safety risks.)",
    "ref_axis": "accuracy",
    "ref_point": -10,
    "gen_criterion": "Mentions the importance of consulting a doctor before using second-generation antihistamines for chronic urticaria.",
    "gen_axis": "context_awareness",
    "gen_point": 5,
    "similarity": 0.8989,
    "point_diff": 15,
    "score": 0.0,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "Cites Simons et al. (2003) study claiming safety of high-dose fexofenadine in elderly patients with chronic urticaria when this specific study is not present in the evidence base. (Justification: Fabricated or misattributed citations undermine credibility.)",
    "ref_axis": "accuracy",
    "ref_point": -3,
    "gen_criterion": "Provides a list of potential medications for chronic urticaria without considering the user's specific situation.",
    "gen_axis": "instruction_following",
    "gen_point": -4,
    "similarity": 0.6192,
    "point_diff": 1,
    "score": 0.619,
    "similar_match": true,
    "axis_match": false
  }
]